All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
#EHA2024: Phase I/II trials in multiple myeloma
To update you on the exciting content presented at the European Hematology Association (EHA) 2024 Congress, we have collated our social media coverage. Catch up with our live social media relating to phase I/II trials in multiple myeloma here.
CONGRESS #EHA2024 | Wilfried Roeloffzen @umcg presents initial efficacy and safety findings of the phase II CARTITUDE-2 study, evaluating ciltacabtagene autoleucel ± lenalidomide maintenance in pts with NDMM with suboptimal response to frontline ASCT (N=17). MRD negativity was… pic.twitter.com/vEBGgzFdX3
— Multiple Myeloma Hub (@MM_Hub) June 15, 2024
CONGRESS #EHA2024 | Xavier Leleu @CHU_de_Poitiers presents efficacy and safety of cohort 2b of the phase II KarMMa-2 study (NCT03601078) investigating ide-cel in pts with NDMM (N=31).
— Multiple Myeloma Hub (@MM_Hub) June 15, 2024
▪️ The primary endpoint of CRR was achieved in 71% pts.
▪️ ORR was 93.5%.
▪️ MRD negativity in… pic.twitter.com/ClTllWHmJc
CONGRESS #EHA2024 | @myelomaMD @MayoClinic highlights initial results from the ongoing phase I/II CAMMA 2 trial. Cevostamab showed promising activity and a manageable safety profile in patients with R/R MM who are triple-class refractory and received a prior BCMA-targeted agent.… pic.twitter.com/101KVE7LoX
— Multiple Myeloma Hub (@MM_Hub) June 16, 2024
CONGRESS #EHA2024 | Katja Weisel, University Medical Center Hamburg-Eppendorf, presents results from a phase I trial of ABBV-383 in patients with R/R MM. The optimal therapeutic dose of 60mg Q4W ABBV-383 monotherapy demonstrated promising efficacy. #mmsm #myeloma #MedicalCongress pic.twitter.com/FtS5QUkctI
— Multiple Myeloma Hub (@MM_Hub) June 16, 2024
CONGRESS #EHA2024 | @Slentzsch @Columbia @columbiacancer discusses results from the phase I/II LINKER-MM1 trial of linvoseltamab monotherapy in patients with R/R MM. Linvoseltamab demonstrated high efficacy and a tolerable safety profile in patients with R/R MM. #mmsm #myeloma… pic.twitter.com/rUVbAPI6eG
— Multiple Myeloma Hub (@MM_Hub) June 16, 2024
CONGRESS | POSTER | #EHA2024 | Katarina Uttervall discusses longer-term follow-up of patients with RRMM receiving prophylactic tocilizumab (n=24) for reduction of CRS in the phase I/II MAJESTEC-1 study. Prophylactic tocilizumab reduced Grade 1/2 CRS from 72.1 to 25%. #mmsm… pic.twitter.com/xPkoumpkNL
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Mohamad Mohty @Mohty_EBMT shares long-term survival outcomes from the phase II MagnetisMM-3 study of elranatamab in patients with RRMM, N=123. ORR remained at 61%, with median DoR not reached. #mmsm #myeloma #MedicalCongress pic.twitter.com/FDjz9FIgSb
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Leo Rasche @RascheLeo shares long-term efficacy and safety results from the phase I/II MONUMENTAL-1 study of talquetamab (TAL) in patients with RRMM, N=375. ORR ≥70% in TCR-naïve and 67% in prior TCR. #mmsm #myeloma #MedicalCongress pic.twitter.com/n6udlYNyn3
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Emma Searle @DrEmmaSearle presents results from the phase IB MONUMENTAL-2 study evaluating the efficacy and safety of talquetemab (TAL) in combination with pomalidomide (POM) in patients with RRMM, N=35. ORR 88.6%. #mmsm #myeloma #MedicalCongress pic.twitter.com/n7mv9p694q
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
CONGRESS | POSTER | #EHA2024 | Luciano Costa @End_myeloma shares preliminary results from the phase I/II CA057-003 trial evaluating oral, triplet combinations in patients with RRMM. Mezigdomide (MEZI) + tazmetostat (TAZ) + dexamethasone (DEX) showed promising efficacy and safety.… pic.twitter.com/QgIpQzoXmr
— Multiple Myeloma Hub (@MM_Hub) June 17, 2024
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content